AI-based plan to monitor kidney transplant function
Part of Immune system & allergy, Kidney & urinary clinical trials.
This trial uses a personalized approach (including tacrolimus medication planning and monitoring) to better understand how a kidney transplant is doing. It may help your transplant team tailor care to your kidney function over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older and have kidney failure (end-stage renal disease)
- You received a kidney transplant from a deceased donor (first or later transplant)
- Your transplant team expects you to take tacrolimus as your main immune-suppressing medicine
- You can read and sign an informed consent form and follow study visits
- You can stay in follow-up with the transplant center for up to 15 months after transplant
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well a new blood test works to monitor kidney health after a transplant. It might help doctors catch problems early without needing a biopsy.
This study tests a new way to monitor harmful antibodies after a kidney transplant. It may help prevent transplant rejection over time.
This trial tests a new treatment using your own immune cells, called tolerogenic dendritic cells, to help your body accept a kidney transplant. It is designed for people who are highly sensitized and have a very hard time finding a matching donor kidney.
This Phase 2 study looks at whether blood test “biomarkers” can guide safely changing anti-rejection medicines after an ABO-compatible kidney transplant. It may help some people reduce certain medicines while keeping the new kidney protected from rejection.
This study follows people who are getting a kidney transplant (first or later) to better understand how the body recovers, using health tracking and “gene/protein” (proteogenomic) information. It may help doctors predict complications and improve care after transplant.
This trial uses DNA testing and gene expression profiling to see if kidney transplant recipients can safely switch to a belatacept-only immunosuppression regimen. The goal is to simplify your anti-rejection drugs while keeping your kidney healthy.
Hear when a new Kidney Transplant Rejection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.